Bradley Pharmaceuticals — Investor Presentation (April 2007)
30 slides from Bradley Pharmaceuticals's investor presentation, Apr 11, 2007
Slide 1: New Horizons, New Accomplishments
New Horizons, New Accomplishments &} BRADLEY PHARMACEUTICALS, INC.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates w
Slide 3: Company Overview
Company Overview Unique specialty pharmaceutical company committed to adding value Founded: 1985, Daniel Glassman, President and CEO Operating segments: Dermatology Podiatry Gastroenterology OB/GYN May 2003, BDY lists on NYSE from Nasdaq Employees (1) : 301 (1) As of December 31, 2006
Slide 4: Company Overview: Sales Growth and Management Team
Company Overview Strong track record of sales growth 2006 Net Sales: $ 144.8 million CAGR (1) : 33.4% since 2001 Experienced Management Team (1) Compound annual growth rate (CAGR) from 2001 to 2006 Name Title Experience (yrs) Daniel Glassman President and CEO Brent Lenczycki VP, Chief Financial Offi
Slide 5: Company Overview: Net Sales
Company Overview Net Sales 2004 2005 2006
Slide 6: Company Overview: Gross Profit & Operating Income
Company Overview Gross Profit & Operating Income (1) (1) Operating income is net sales minus cost of sales, SG&A, R&D and D&A expense (excludes interest expense, interest income and income tax expense). (2) Includes $3,475,000 compensation cost for share-based payment arrangements, $2,100,000 in leg
Slide 7: Company Overview: Net Income and EPS
Company Overview Net Income and EPS, Fully Diluted (1) (1) 2004, 2005, 2006 EPS fully diluted calculations based on 18,410,000, 17,950,000, and 16,550,000 diluted shares. (2) Includes $13,475,000 compensation cost for share-based payment arrangements, $2,100,000 in legal and advisor fees relating to
Slide 8: Product Returns and Inventory Improvement Initiatives
Company Overview Product Returns and Inventory Improvement Initiatives Continue efforts to reduce wholesaler inventory levels Improve effective dating of products – In progress Expiration date testing Optimize product production schedules Raised minimum dating requirements prior to shipping Shift pr
Slide 9: Success built on core marketing and sales expertise
Company Overview Success built on core marketing and sales expertise Late-stage product candidates that upon approval leverage our sales and marketing capabilities New products through lifecycle management and new indications for existing brands Brands that fill unmet physician and patient needs
Slide 10: New Horizons, New Accomplishments
New Horizons, New Accomplishments
Slide 11: Doak Dermatologics - Major Brands
Commercialize Adoxa ® Rosula ® Zoderm ® Solaraze ® Gel Keralac TM Kerol TM Carmol ® Doak Dermatologics - Major Brands 2006 Net Sales = $114.5 M 48.5% 18.4% 20.6% 5.0% 7.5%
Slide 12: Kenwood Therapeutics - Major Brands
Commercialize Pamine ® AnaMantle HC ® Flora-Q ® Glutofac ZX/MX ® Kenwood Therapeutics - Major Brands 2006 Net Sales = $30.3 M 85.5% 6.8% 7.7%
Slide 13: Synergistic Promotion and Sales Execution
Commercialize Synergistic Promotion and Sales Execution
Slide 14: Sales Force Productivity
Commercialize Sales Force Productivity National Field Force Focused on “QAD” Selling Model
Slide 15: Leverage Dynamic Physician Relationships: Kenwood Therapeutics
Commercialize Leverage Dynamic Physician Relationships Kenwood Therapeutics Gastroenterology and Colon Rectal Surgery Headquarters Physician Territory Major Conference Exhibitor Digestive Disease Week American College of Gastroenterology Sponsored more than 60 GE specialty society meetings OB/GYN Ma
Slide 16: Leverage Dynamic Physician Relationships: Doak Podiatry
Commercialize Leverage Dynamic Physician Relationships Doak Dermatologics Podiatry “See the Podiatrist” Campaign Major Sponsor, Superbones/Superskin™ CME Pharmacists “Profiles in Pharmacy” Campaign Leaders in Community Pharmacy Advisory Board Physicians Assistants/Dermatology CME Sponsorship Major S
Slide 17: Leverage Dynamic Physician Relationships: Dermatology
Commercialize Leverage Dynamic Physician Relationships Doak Dermatologics Dermatology Headquarters Physician Territory Key Opinion Leader Endorsements Skin Cancer Screening Tour Conducted more than 5,500 free screenings Generated more than 55 million media impressions regarding importance of seeing
Slide 18: Growing, Patent-Protected Brands: Solaraze Gel
Commercialize Growing, Patent-Protected Brands Solaraze ® Gel (diclofenac sodium 3%) Indication: Actinic Keratosis Strong brand growth 2006 Net Sales: $23.6 million, up 80% over 2005 Estimated market share: 17.5% (1) Safety and efficacy: 90% mean decrease in target lesions vs. baseline 58% of patien
Slide 19: New Horizons, New Accomplishments
New Horizons, New Accomplishments
Slide 20: Develop Brands Through Lifecycle Management
Develop Develop Brands Through Lifecycle Management Introduce new products and line extensions filling unmet patient and physician needs
Slide 21: Develop Brands Through Clinical Support
Develop Develop Brands Through Clinical Support Doak Dermatologics - Current and on-going studies: Keralac™ Nail Gel: Brittle Nails (Dr. Scher) Dystrophic Nails (Dr. Robbins ) Solaraze ® Gel: Effectiveness Post Cryosurgery, multi-center (Dr. Rigel) AK of the Lip Study (Dr. Nelson) Proof of Concept,
Slide 22: New Horizons, New Accomplishments
New Horizons, New Accomplishments
Slide 23: Merger/Acquisition/Licensing Activity
In-License Merger/Acquisition/Licensing Activity – Last 5 Yrs Merger/Acquisition/Licensing Activity – Prior Com pany Transactio n Adams Res piratory ENTSOL ® BioSante Elestrin TM Lundbeck Flora-Q ® MediGene AG Veregen TM Com pany Transaction Mission Phar macal AnaMantle HC ® Quintiles Bioglan SkyePh
Slide 24: Patent-Protected Brands: Veregen
In-License Patent-Protected Brands Veregen TM (sinecatechins) In-licensed U.S. rights from MediGene AG Indication: Treatment of external genital and perianal warts FDA approval: 10/31/06 Hypothesized mode of action (1) includes anti-inflammatory, antiviral, anti-oxidant and immune modulatory Market
Slide 25: Veregen: Advantages over Aldara
Summary of Combined Pivotal Data In-License Patent-Protected Brands Veregen TM : Advantages over Aldara ® Clears newly emerging warts Relatively high clearance in males Relatively low recurrence rates Aldara ® (1) Veregen TM Source: MediGene AG 13 – 27.5% (3) 6.2% Recurrence Rate: Not Investigated 5
Slide 26: Veregen: Better Safety Profile vs. Aldara
Summary of Combined Pivotal Data In-License Patent-Protected Brands Veregen TM : Better Safety Profile vs. Aldara ® Systemic side effects unlikely Skin reactions mild, and decrease with time No requirements for drug holidays Aldara ® (1) Veregen TM Source: MediGene AG •3x/week •3x/day (compliance 90
Slide 27: Patent-Protected Brands: Elestrin Gel
In-License Patent-Protected Brands Elestrin TM (estradiol) Gel In-Licensed U.S. rights from BioSante Pharmaceuticals Indication: Treatment of moderate-to-severe vasomotor symptoms in menopausal women FDA approval: 12/15/06 Market considerations: Transdermal gel offering the lowest effective dose of
Slide 28: Elestrin Gel: Advantages over Other Estradiol Therapies
In-License Application Site Lowest Effective Dose Packaging Formulation Product Patent-Protected Brands Elestrin TM Gel: Advantages over oral estradiol therapies Reduced risk of thromboembolic events Advantages over estradiol patches Less irritating Cosmetically appealing Dose titration possible wit
Slide 29: Why Bradley Pharmaceuticals
Why Bradley Pharmaceuticals Successful track record of strong sales and profits Experienced senior management team Well established relationships with key specialty physician opinion leaders and physician audiences Winning strategy for creating value built upon core marketing and sales expertise, wh
Slide 30: New Horizons, New Accomplishments
New Horizons, New Accomplishments &} BRADLEY PHARMACEUTICALS, INC.
Bradley Pharmaceuticals — Investor Presentation (April 2007) on 6ix